Oxford-based artificial intelligence (AI) drug discovery company Exscientia has announced it has entered into three-year partnership with Celgene for an initial upfront payment of $25m.
21 March 2019 AI
21 March 2019 News
The European Medicines Agency has advised patients and clinicians to not exceed the 5mg twice daily recommendation dose of Pfizer’s Xeljanz (tofacitinib) for rheumatoid arthritis.
19 March 2019 Comment
Pfizer seemed unmoved by the safety alert issued by the FDA and positioned Xeljanz as the first and only JAK inhibitor approved for moderate to severe ulcerative colitis.
8 March 2019 News
Johnson & Johnson’s subsidiary Janssen Pharmaceuticals and ViiV Healthcare have revealed 48 week data from two pivotal Phase III trials showing injections of their long-acting, monthly combination of cabotegravir and...
6 March 2019 Comment
PVX108 is a novel intradermal immunotherapy vaccine in a clinical trial for in peanut allergic individuals.
5 March 2019 News
A second patient has been cleared of the most aggressive, common form of human immunodeficiency virus (HIV), HIV-1 following a bone marrow transplant from a donor with a rare genetic...
18 February 2019 Comment
Globally, there are 633 marketed products for allergic conjunctivitis.
15 January 2019 Comment
Despite positive data observed with Catalyst Pharmaceuticals’ Firdapse in a proof-of-concept investigator-sponsored trial in muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG), the results’ clinical relevance is hard to determine.